6. Parkinson disease
2,123 clinical trials,   2,046 drugs   (DrugBank: 324 drugs),   183 drug target genes,   198 drug target pathways

Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
21 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04117178
(ClinicalTrials.gov)
February 4, 202030/9/2019Monitoring Anti-Dementia Drugs by Serum LevelsMonitoring Anti-Dementia Drugs by Serum Levels: Importance of Serum Levels, Drug-monitoring, Side-effects, Clinical Efficacy and Compliance (Translation of Official Danish Title)Dementia;Dementia With Lewy Bodies;Dementia in Parkinsons Disease;Dementia Alzheimers;Alzheimer DiseaseDrug: Donepezil;Drug: Memantine;Diagnostic Test: Measurement of serum level of anti-dementia drugZealand University HospitalEpilepsihospitalet FiladelfiaRecruiting18 YearsN/AAll110Phase 4Denmark
2NCT03599726
(ClinicalTrials.gov)
July 30, 201829/6/2018Improving Walking Automaticity in Parkinson's Disease: Levodopa or DonepezilImproving Walking Automaticity in Parkinson's Disease: Levodopa or DonepezilParkinson DiseaseDrug: Donepezil;Drug: PlaceboOregon Health and Science UniversityMedical Research Foundation, OregonCompleted50 Years90 YearsAll20Early Phase 1United States
3EUCTR2017-002707-10-DK
(EUCTR)
10/04/201803/11/2017Measurements of drug concentration in the blood for anti-dementia drugs, in order to improve efficacy and reduce side-effectsSerum-monitoring of anti-dementia drugs, and the relevance to side-effects, clinical efficacy and compliance Dementia in Alzheimers Disease, Parkinsons Disease and Dementia with Lewy Bodies
MedDRA version: 20.0;Level: PT;Classification code 10012271;Term: Dementia Alzheimer's type;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 20.0;Level: LLT;Classification code 10012284;Term: Dementia due to Parkinson's disease;Classification code 10067889;Term: Dementia with Lewy bodies;Classification code 10075174;Term: Mixed dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Memantin Orion
INN or Proposed INN: MEMANTINE
Product Name: Donepezil Sandoz
Product Code: 25330
INN or Proposed INN: DONEPEZIL
Regional Dementia Research Centre, Dept of NeurologyNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
110Phase 4Denmark
4NCT03011476
(ClinicalTrials.gov)
April 11, 201727/12/2016Effect of Acetylcholinesterase Inhibitors on the Gait of the Patients With Parkinson DiseaseEffect of Acetylcholinesterase Inhibitors on the Gait of the Patients With Parkinson Disease Characterized by Postural Instability and Gait DisturbanceParkinson DiseaseDrug: Donepezil;Drug: PlacebosKyung Hee University HospitalNULLUnknown status40 Years75 YearsAll20Phase 4Korea, Republic of
5NCT02857244
(ClinicalTrials.gov)
November 201625/7/2016A Multidisciplinary Approach to Manage Gait Difficulty in Parkinson PatientsA Multidisciplinary Approach to Manage Gait Difficulty in Parkinson PatientsParkinson's DiseaseDrug: Duloxetine;Drug: Donepezil;Drug: ModafinilUniversity of ChicagoNULLWithdrawn18 Years100 YearsAll0Phase 2United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT02415062
(ClinicalTrials.gov)
July 201514/3/2015The Efficacy and Safety Study of High Dose Donepezil in Parkinson's Disease With DementiaThe Efficacy of 23mg Versus 10mg of Donepezil in ParkInson's Disease With DementiaParkinson's DiseaseDrug: DonepezilInje UniversityNULLRecruiting50 Years80 YearsBoth150Phase 2Korea, Republic of
7NCT02450786
(ClinicalTrials.gov)
June 201514/5/2015Effect of Donepezil on Cognition in Parkinson's Disease With Mild Cognitive Impairment (PD-MCI)Parkinson's DiseaseDrug: DonepezilYonsei UniversityNULLActive, not recruiting40 YearsN/AAll80Phase 2Korea, Republic of
8NCT02206620
(ClinicalTrials.gov)
July 201429/7/2014Effects of Cholinergic Augmentation on Measures of Balance and GaitEffects of Cholinergic Augmentation on Measures of Balance and GaitParkinson's DiseaseDrug: DonepezilOregon Health and Science UniversityMichael J. Fox Foundation for Parkinson's ResearchCompleted30 YearsN/AAll49Phase 2United States
9JPRN-UMIN000010752
2013/05/1717/05/2013A study on usefulness and safety of donepezil for cognitive function and phychological symptoms of patients with Parkinson's disease and Alzheimer type dementia. Parkinson's diseasedonepezilKansai Medical UniversityNULLComplete: follow-up completeNot applicableNot applicableMale and Female50Not selectedJapan
10JPRN-UMIN000010778
2013/04/1022/05/2013Delayed start study of donepezil hydrocloride for cognitive decline in Parkinson disease following EDAP-1Delayed start study of donepezil hydrocloride for cognitive decline in Parkinson disease following EDAP-1 - EDAP-2 Parkinson disease5mg donepezil hydroclorideNational Hospital of UtanoNULLComplete: follow-up complete20years-oldNot applicableMale and Female50Not selectedJapan
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11JPRN-UMIN000009958
2013/03/0801/03/2013Effects of donepezil on the prognosis of Parkinson's disease with severe olfactory dysfunction Parkinson's diseaseDonepezil hydrochloride added to standard therapy
Placebo added to standard therapy
National Hospital Organization, Sendai-Nishitaga HospitalNULLComplete: follow-up complete55years-old75years-oldMale and Female200Not applicableJapan
12NCT01014858
(ClinicalTrials.gov)
January 201316/11/2009Multi-centre UK Study of the Acetylcholinesterase Inhibitor Donepezil in Early Dementia Associated With Parkinson's DiseaseMulti-centre UK Study of the Acetylcholinesterase Inhibitor Donepezil in Early Dementia Associated With Parkinson's DiseaseParkinson's DiseaseDrug: DonepezilNewcastle-upon-Tyne Hospitals NHS TrustUniversity of Newcastle Upon-Tyne;University of Cambridge;University of Manchester;University of Birmingham;Bangor University;London School of Economics and Political Science;University College, London;Lancashire Care NHS Foundation Trust;Newcastle University;King's College LondonTerminated18 YearsN/AAll64Phase 3United Kingdom
13EUCTR2009-015170-35-GB
(EUCTR)
27/01/201221/12/2011Study across 22 UK hospitals investigating if a drug called Donepezil Hydrochloride can help people with an early form of Parkinson's Disease dementia.Multicentre UK Study of the Acetylcholinesterase Inhibitor Donepezil in Early Dementia Associated with Parkinson's Disease (MUSTARDD-PD) - Donepezil in Early Dementia Associated with Parkinson's Disease Parkinson's disease with mild dementia (PDD);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]The Newcastle upon Tyne Hospitals NHS Foundation TrustNULLNot Recruiting Female: yes
Male: yes
500Phase 3United Kingdom
14NCT01521117
(ClinicalTrials.gov)
December 201112/1/2012The Effect of Donepezil on Gait and Balance in Parkinson's DiseaseA Randomized, Double-blind, Placebo Controlled, Crossover Study to Evaluate the Effect of Donepezil on Gait and Balance in Parkinson's DiseaseParkinson's DiseaseDrug: DonepezilOregon Health and Science UniversityNULLRecruitingN/AN/ABoth12Phase 4United States
15JPRN-UMIN000005403
2011/04/0108/04/2011A Multi-center Randomized Placebo-controlled Double-blinded Study for the Efficacy of Donepezil against Psychosis in Parkinson Disease Parkinson disease5mg of donepezil hydrochloride
placebo
Designated Research, National Hospital OrganizationNULLComplete: follow-up complete20years-old80years-oldMale and Female142Phase 3Japan
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16JPRN-UMIN000003080
2010/01/0130/01/2010Double Blind Study for Effects of Donepezil Hydrochloride on Parkinson's Disease Parkinson's diseaseDonepezil hydrochloride (3mg for 2 weeks, 5mg for 2 weeks)
Placebo
Clinical Research Center, Utano National Hospital, National Hospital OrganizationNULLComplete: follow-up complete40years-old75years-oldMale and Female30Not applicableJapan
17NCT00912808
(ClinicalTrials.gov)
October 20052/6/2009Cholinergic Augmentation in Frequently Falling Subjects With Parkinson's DiseaseA Study of Cholinergic Augmentation in Frequently Falling Subjects With Parkinson'sParkinson's DiseaseDrug: Donepezil;Drug: Sugar Pill (placebo)Oregon Health and Science UniversityNULLCompleted21 YearsN/AAll23N/ANULL
18EUCTR2004-003355-39-AT
(EUCTR)
14/09/200408/10/2004A 52-week, multicentre, open label extension study of the safety, tolerability and efficacy of donepezil (Aricept) in Parkinson's disease patients with dementia.A 52-week, multicentre, open label extension study of the safety, tolerability and efficacy of donepezil (Aricept) in Parkinson's disease patients with dementia. Dementia associated with Parkinson's diseaseTrade Name: Aricept 5 mg-Filmtabletten
Product Name: Aricept 5mg-Filmtabletten
Eisai LimitedNULLNot RecruitingFemale: yes
Male: yes
468Austria
19NCT01327859
(ClinicalTrials.gov)
March 200330/3/2011Safety, Tolerability, and Efficacy of Donepezil (Aricept) in Parkinson' s Disease (PD) Patients With DementiaA 52-week, Multicentre Open Label Extension Study of the Safety Tolerability and Efficacy of Donepezil (Aricept) in Parkinson's Disease (PD) Patients With DementiaParkinson's Disease;DementiaDrug: Prior Donepezil 5mg;Drug: Prior Donzepezil 10mg;Drug: Prior PlaceboEisai Inc.NULLCompleted40 YearsN/ABoth357Phase 3United Kingdom
20NCT00165815
(ClinicalTrials.gov)
August 200213/9/2005The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With DementiaDementia With Parkinson's DiseaseDrug: ARICEPTEisai LimitedNULLCompleted40 YearsN/ABothPhase 3Germany;Ireland
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
21NCT00030979
(ClinicalTrials.gov)
February 200215/2/2002Donepezil to Treat Dementia in Parkinson's DiseaseDonepezil for Dementia in Parkinson's Disease: A Randomized, Double Blinded Placebo Controlled Crossover TrialParkinson DiseaseDrug: DonepezilNational Institute of Neurological Disorders and Stroke (NINDS)NULLCompletedN/AN/ABoth28Phase 4United States